Company: INMB
Filing Date: 2025-10-30
Form Type: 10-Q
Source: 0001213900-25-104141
Chunk: 41

Company: Inmune Bio, Inc.
Filing Date: 2025-10-30
Form: 10-Q
Item: Part I, Item 1
Chunk 41
---
 may obtain regulatory approval;

    ●
    seek to comply with regulatory standards and laws;

    ●
    maintain, leverage and expand our intellectual property portfolio;

    ●
    hire clinical, manufacturing, scientific and other personnel to support our product candidates development and future commercialization efforts;

    ●
    add operational, financial and management information systems and personnel; and

    ●
    incur additional legal, accounting and other expenses in operating as a public company.

29

Results of Operations 

Comparison of the Three Months Ended September
30, 2025 and 2024

The following table summarizes
our results of operations for the periods indicated:

    Three Months Ended September 30,  

    (in thousands) 
    2025  
    2024  
    Change 
  
    Revenues 
    $-  
    $-  
    $- 
  
    Operating expenses: 

    Research and development 
     4,887  
     10,067  
     (5,180)
  
    General and administrative 
     2,546  
     2,219  
     327 
  
    Total operating expenses 
     7,433  
     12,286  
     (4,853)
  
    Loss from operations 
     (7,433) 
     (12,286) 
     4,853 
  
    Other income, net 
     961  
     193  
     768 
  
    Net loss 
    $(6,472) 
    $(12,093) 
    $5,621 

Research and Development

Research and development expenses
were approximately $4.9 million during the three months ended September 30, 2025, compared to approximately $10.1 million during
the three months ended September 30, 2024. The change in research and development expenses during the three months ending September 30,
2025 compared to the three months ending September 30, 2024 is mainly due to the Company incurring $6.4 million less expenses related
to our Alzheimer’s clinical program due to the Company completing the Phase 2 clinical trial, partially offset by incurring additional
compensation expense of $1.3 million mainly due to costs associated with the termination of employees.

General and Administrative

General and administrative
expenses were approximately $2.5 million during the three months ended September 30, 2025